Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Yousuf Al-Farhat et al.|The Lancet|2018Cited by 1.7k
Dose Escalation Methods in Phase I Cancer Clinical TrialsChristophe Le Tourneau, Lillian L. Siu|JNCI Journal of the National Cancer Institute|2009Cited by 856
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck CancerRavindra Uppaluri, Douglas Adkins, Robert I. Haddad et al.|New England Journal of Medicine|2025Cited by 277
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Christophe Le Tourneau, Martin Schüler et al.|The Lancet Oncology|2023Cited by 195
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trialChristophe Le Tourneau, James L. Gulley|Journal for ImmunoTherapy of Cancer|2018Cited by 165